ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
TransCode Therapeutics Inc

TransCode Therapeutics Inc (RNAZ)

0.38
-0.02
(-5.00%)
Cerrado 27 Abril 3:00PM
0.3801
0.0001
(0.03%)
Fuera de horario: 6:58PM

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Estadísticas y detalles clave

Último Precio
0.3801
Postura de Compra
0.3801
Postura de Venta
0.3861
Volume Operado de la Acción
7,309,532
0.38 Rango del Día 0.5004
0.219565 Rango de 52 semanas 66.33
Capitalización de Mercado [m]
Precio Anterior
0.40
Precio de Apertura
0.409
Última hora de negociación
Volumen financiero
US$ 3,172,877
Precio Promedio Ponderado
0.434074
Volumen promedio (3 m)
7,340,547
Acciones en circulación
23,341,336
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-0.48
Beneficio por acción (BPA)
-0.79
turnover
-
Beneficio neto
-18.55M

Acerca de TransCode Therapeutics Inc

TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regre... TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sede
Wilmington, Delaware, USA
Fundado
-
TransCode Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RNAZ. The last closing price for TransCode Therapeutics was US$0.40. Over the last year, TransCode Therapeutics shares have traded in a share price range of US$ 0.219565 to US$ 66.33.

TransCode Therapeutics currently has 23,341,336 shares in issue. The market capitalisation of TransCode Therapeutics is US$9.34 million. TransCode Therapeutics has a price to earnings ratio (PE ratio) of -0.48.

RNAZ Últimas noticias

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10.101736.53017241380.27840.46810.278469467740.33860801CS
4-0.2226-36.93379790940.60270.670.21956548536340.42025667CS
12-7.6799-95.28411910678.0614.24990.21956573405471.60650037CS
26-20.8587-98.210350867321.238821.943350.21956540845432.79690023CS
52-14.4666-97.439835114914.846766.330.21956528729408.4805199CS
156-65999.6199-99.999424090966000784080.21956521429664708.20282707CS
260-158399.6199-99.99976003791584001848000.219565201202720944.8960856CS

RNAZ - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de TransCode Therapeutics?
El precio actual de las acciones de TransCode Therapeutics es US$ 0.3801
¿Cuántas acciones de TransCode Therapeutics están en circulación?
TransCode Therapeutics tiene 23,341,336 acciones en circulación
¿Cuál es la capitalización de mercado de TransCode Therapeutics?
La capitalización de mercado de TransCode Therapeutics es USD 9.34M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de TransCode Therapeutics?
TransCode Therapeutics ha negociado en un rango de US$ 0.219565 a US$ 66.33 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de TransCode Therapeutics?
El ratio precio/beneficio de TransCode Therapeutics es -0.48
¿Cuál es la moneda de reporte de TransCode Therapeutics?
TransCode Therapeutics presenta sus resultados financieros en USD
¿Cuál es el último beneficio anual de TransCode Therapeutics?
El último beneficio anual de TransCode Therapeutics es USD -18.55M
¿Cuál es la dirección registrada de TransCode Therapeutics?
La dirección registrada de TransCode Therapeutics es 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
¿Cuál es la dirección del sitio web de TransCode Therapeutics?
La dirección del sitio web de TransCode Therapeutics es www.transcodetherapeutics.com
¿En qué sector industrial opera TransCode Therapeutics?
TransCode Therapeutics opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
WWWW International Inc
US$ 0.395
(167.62%)
223.58M
OMEXOdyssey Marine Exploration Inc
US$ 1.4979
(75.79%)
285.65M
RTCBaijiayun Group Ltd
US$ 0.3244
(74.88%)
263.23M
GREEGreenidge Generation Holdings Inc
US$ 1.3197
(53.92%)
5.84M
SXTCChina SXT Pharmaceuticals Inc
US$ 2.28
(44.30%)
38.04M
CGTLCreative Global Technology Holdings Ltd
US$ 1.5197
(-75.09%)
3.88M
TOIIWOncology Institute Inc
US$ 0.1015
(-40.22%)
156.14k
COEPCoeptis Therapeutics Holdings Inc
US$ 7.70
(-38.25%)
716.99k
INTSIntesity Therapeutics Inc
US$ 0.56
(-37.78%)
3.21M
SMMTSummit Therapeutics Inc
US$ 23.47
(-36.05%)
24.67M
GNLNGreenlane Holdings Inc
US$ 0.012699
(-15.34%)
355.22M
AGMHAGM Group Holdings Inc
US$ 0.0477
(22.31%)
340.91M
OMEXOdyssey Marine Exploration Inc
US$ 1.4979
(75.79%)
285.65M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 10.455
(19.62%)
266.95M
RTCBaijiayun Group Ltd
US$ 0.3244
(74.88%)
263.23M

RNAZ Discussion

Ver más
MartinLutherKing MartinLutherKing 24 horas hace
Email the rodent Tom Fitzreversal, Tell him to release good news and to do it multiple times next week, instead of raping investors all his career for his personal reasons

https://contactout.com/Tom-Fitzgerald-14878949

https://clinicaltrials.gov/study/NCT05908773
👍️0
Atomic_Insider Atomic_Insider 2 días hace
Everything smells of shit in the money laundering scam milk the cash cow machine Where’s The patient that has remained on study the longest has, to date, received 7 doses each approximately 28 days apart over the approximately 7 months that this patient has been on study.
👍️0
Atomic_Insider Atomic_Insider 2 días hace
The shorts are in bed with the money laundering management so the criminals can funnel the cash cow strait in their pockets all their careers and pretend to be the vicitims of their own crimes.. Live or die by the sword for these criminals in management, balls to the walls in a federal state penn with the gorillas tearing up their ass holes
👍️0
zeusgodmd zeusgodmd 2 días hace
17 million traded in last 2 days good change off hands
👍️0
guitartrader guitartrader 2 días hace
I am not disagreeing with you. There are forces that seem to want to push this upward. That is all I am saying. I agree that we need some updates on the treatment. I also agree this has been beat down. We all know that can be a company and it's selling but can also be ruthless shorts. Time will tell which it is. Again I am not disagreeing with the need for the company to update shareholders.
👍️0
Atomic_Insider Atomic_Insider 2 días hace
Where is the patient that has remained on study the longest has, to date, received 7 doses each approximately 28 days apart over the approximately 7 months that this patient has been on study. you dirty scam artists fraudsters
👍️0
Atomic_Insider Atomic_Insider 2 días hace
The wild wild west has already started bud they don t realize what’s
about to happen with these dirty criminal money laundering cash cow milking fraud artists of the scientific community in management. When your a criminal you must live by the sword, balls to the walls, do or die, where is the patient that has remained on study the longest has, to date, received 7 doses each approximately 28 days apart over the approximately 7 months that this patient has been on study. Nothing else maters of their bullshit stories
👍️0
guitartrader guitartrader 2 días hace
I agree. I see this being pushed to a dollar or above for whatever reason one wants to believe.
👍️0
Atomic_Insider Atomic_Insider 2 días hace
The fraud artists of the micro Rna nobel prize scam have their heads in a vice grip
Where is the patient that has remained on study the longest has, to date, received 7 doses each approximately 28 days apart over the approximately 7 months that this patient has been on study you dirty rats
👍️0
zeusgodmd zeusgodmd 2 días hace
Wild West starts next week vote on Friday if cancelled maybe big dawgs bring it above 1$
👍️ 1
Atomic_Insider Atomic_Insider 2 días hace
The fraud artists in management love to screw their shareholders all their careers , do your DD these criminals don’t own any shares in their own company, Fill up their pockets milking the cash cow while they screw shareholders for a profession and are very passionate in what they do…
👍️0
Atomic_Insider Atomic_Insider 2 días hace
Exactly these money laundering criminals in management love to milk the cash cow strait in their pockets giving the hope of a cure to cancer… Heads in the vice grip, bàlls to the walls, in the criminal world you live by the sword.. they will all get busted for fraud
👍️0
guitartrader guitartrader 2 días hace
Short volume is climbing.  Risky right now for them imo.  I think we are heading to a dollar plus short term just on price action.
👍️0
power11 power11 2 días hace
THEY DON'T WANT TP RELEASE BAD NEWS, THAT'S MY TAKE ON IT !!!!
👍️0
Atomic_Insider Atomic_Insider 2 días hace
The world wants to know where is the patient that has remained on study the longest has, to date, received 7 doses each approximately 28 days apart over the approximately 7 months that this patient has been on study. The rest is all bullshit to this money laundering cash cow machine designed to screw investors since inception so they can fill their pockets and FTW
👍️0
surfkast surfkast 2 días hace
Your caps lock is broken.
I was just commenting on what I saw. Still moving up today.
👍️0
guitartrader guitartrader 2 días hace
I think the price action says be cautious but you can make some money here. Who knows what could happen here in spite of the companies business practices.
👍️0
power11 power11 2 días hace
I'LL MAKE SIMPLE AND CLEAR : IF THERE WAS ANYTHING POSITIVE, YOU WOULD HAVE
HEARD ABOUT !! THE STOCK PRICE ACTION SAYS TO ME : STAY AWAY !!!!!!!!!!!!!!!!!!!!1
👍️0
guitartrader guitartrader 2 días hace
We can question business practices all day long. There could be shady stuff. In the end I personally think that there is either going to be a massive short squeeze here OR we get some good news. Trade cautiously but at least have a plan.
👍️0
Atomic_Insider Atomic_Insider 2 días hace
Question for Zdravka Medarova, PhD Founder/Chief Scientific Officer a money laundering specialist milking the cash cow dry since inception funneling millions strait in your pockets, while you screw all your shareholders with R/S’s where is the patient that has remained on study the longest has, to date, received 7 doses each approximately 28 days apart over the approximately 7 months that this patient has been on study… your a dirty rodent CSO founder in bed with all the short criminal funders that screws investors as a passion & profession rot in hell in jail for fraud
👍️0
Stks_Not_Toys Stks_Not_Toys 3 días hace
See that ignore button on the left, click it and he's gone.
👍️0
Atomic_Insider Atomic_Insider 3 días hace
It’s not towards you bud, it’s towards the criminal money laundering Chairman feces face Calais and turd masters cook the books CEO Fitzgerald scam artist money laundering specialist that milked this company over 150M strait in their pockets since inception and screwed shareholders all their careers with R/S, while they own no shares of the company., they pretend to be victims of there own crimes. Jail is where they belong for fraud on all counts in a federal state penn getting their asses rapped by gorillas
👍️0
guitartrader guitartrader 3 días hace
Wow pretty aggressive talk towards me. I wasn't talking to you or replying to a post of yours. Just commenting on the price action and interested in which way it will go. Do you have a crystal ball?
👍️0
Atomic_Insider Atomic_Insider 3 días hace
Who gives a shit,..Shareholders lost it all with RNAZ …Its the money laundering scam machine of the scientific nobel prize Mi-Rna community, Its corporate founders specialize in funneling the cash cow strait in their pockets while they act like they are the victims of this crime, These criminals specialize in R/S all their careers while they dump the garbage on all their shareholders , the criminals in management own no shares of the company, they only love to milk the cash cow dry strait in their pockets
👍️0
surfkast surfkast 3 días hace
Interesting. Up 29% with tons of T trades and odd lots.
👍️0
Atomic_Insider Atomic_Insider 3 días hace
Feces face Chairman Calais & Master turd cook the books Ceo Fitzgerald the criminal money laundering specialists.. where is the orphan drug status approval for rapid fast track approval with CSO Medarova, PhD
Founder/Chief Scientific Officer of the money laundering scam machine fill your pockets and run for cover with the shorts in bed with you naked
👍️0
Atomic_Insider Atomic_Insider 3 días hace
It’s Live or die by the sword in the criminal world for all of the criminals in management fraud artist money laundering specialists, it’s very simple forget all your bullshit, where’s that patient that has remained on study the longest has, to date, received 7 doses each approximately 28 days apart over the approximately 7 months that this patient has been on study??

TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

PR Newswire

BOSTON, March 13, 2025

Clinical trial Safety Review Committee (SRC) approved opening of Cohort 4 based on favorable safety data from the three patients comprising Cohort 3
No significant safety or dose limiting toxicities reported in Cohorts 1, 2, or 3
Patients currently being evaluated for Cohort 4 eligibility
PK and PD data from patients in Cohort 1 and Cohort 2 consistent with preclinical results and results from Phase 0 clinical trial
BOSTON, March 13, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the Safety Review Committee (SRC) monitoring its Phase I clinical trial has unanimously approved opening of the fourth cohort of patients based on the SRC's favorable review of Cohort 3 safety data. The therapeutic candidate being evaluated, TTX-MC138, is a first-in-class therapeutic designed to treat multiple metastatic cancers using antisense technology. The dose administered to the fourth cohort, as originally planned in the clinical protocol, will be approximately fifty percent higher than the dose administered in the third cohort.

Logo (PRNewsfoto/TransCode Therapeutics, Inc.)

Under the clinical protocol, patients may remain on study absent safety events or disease progression. Out of 9 patients treated with TTX-MC138 in the first three cohorts, 6 remain on study for continued treatment since there have been no dose limiting toxicities or disease progression with these patients. The patient that has remained on study the longest has, to date, received 7 doses each approximately 28 days apart over the approximately 7 months that this patient has been on study. In addition to approving opening the fourth cohort, the SRC approved enrollment of additional patients in Cohort 3 to build upon the safety profile of TTX-MC138. Further, Cohort 1 and 2 data analysis for both pharmacokinetic (PK) and pharmacodynamic (PD) activity is ongoing and suggests that TTX-MC138 demonstrates a PK/PD profile consistent with preclinical results and results from TransCode's Phase 0 clinical trial. Preliminary results from Cohort 2 confirmed observations from the Phase 0 trial and from Cohort 1 that the drug candidate shows evidence of activity in patient blood. Preliminary PK analysis suggests that dose levels 0.8-1.6 mg/kg, the levels administered to Cohorts 1 and 2, could represent an efficacious range.

"SRC approval to open the fourth cohort and expand enrollment in Cohort 3 is an important advancement for the clinical trial. It will provide an opportunity to obtain additional safety and PK/PD data, inform the dose expansion stage of the clinical trial and may allow us to obtain initial evidence of clinical activity" commented Sue Duggan, TransCode's Senior Vice President of Operations. Duggan added, "Enrollment into the study continues based on the cumulative safety data review. Eligible subjects may now be screened and scheduled in Cohort 4 for treatment with the next dose level of TTX-MC138 while preliminary data analysis continues."

About TTX-MC138

TTX-MC138 is a first-in-class therapeutic candidate that targets microRNA-10b, a micro-RNA widely believed to be a driver of metastatic disease. TransCode's 2023 Phase 0 clinical trial produced evidence of delivery of a radiolabeled version of TTX-MC138 to metastatic lesions and pharmacodynamic activity, even at a microdose of the drug candidate, suggesting a broad therapeutic window for TTX-MC138.

About the Trial

TransCode's Phase 1 clinical trial is a multicenter, open-label, dose-escalation and dose-expansion study, designed to generate critical data to support evaluation of the safety and tolerability of TTX-MC138 in patients with a variety of metastatic solid cancers. While not an endpoint, the trial may provide early evidence of clinical activity of TTX-MC138. The trial comprises an initial dose-escalation stage followed by a dose-expansion stage. The primary objective of the dose-escalation stage is to evaluate the safety and tolerability of escalating dose levels of TTX-MC138. In the dose-expansion stage, the safety, tolerability and anti-tumor activity of TTX-MC138 will be further evaluated in certain tumor types selected based on preliminary results from the dose-escalation stage.

Further information is available at www.clinicaltrials.gov NCT Identifier: (NCT06260774).

About TransCode Therapeutics

TransCode is a clinical-stage oncology company focused on treating metastatic disease. The company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
👍️0
guitartrader guitartrader 3 días hace
Wow interesting price action today. I smell a massive short squeeze coming! Maybe?
👍️0
Atomic_Insider Atomic_Insider 3 días hace
The fraud artists in management have played the dirtiest tricks in the books, their heads are in a vice grip now, when you live in the criminal world you have to live by the sword, balls to the walls, where is that patient that has remained on study the longest has, to date, received 7 doses each approximately 28 days apart over the approximately 7 months that this patient has been on study..where are those results before you decide to keep frauding investors with your money laundering cash cow designed to funnel it all in managements pockets
👍️0
Atomic_Insider Atomic_Insider 3 días hace
Forget about their 4th cohort bullshit, the world wants to know where’s that patient that has remained on study the longest has, to date, received 7 doses each approximately 28 days apart over the approximately 7 months that this patient has been on study..where are those results before you decide to keep frauding investors with your money laundering cash cow designed to funnel cash strait in managements pockets you dirty rat fraud artists Chairmain feces Calais and cook the books specialist turd CEo Fitzgerald
👍️0
Here Today Here Today 3 días hace
Good question. Since 28 days have almost passed since the last 28 day update, would be nice to know if the patient is alive, still on the trial progressing forward, etc etc.
👍️0
Atomic_Insider Atomic_Insider 3 días hace
Big pharma don’t deal with money laundering fraud artists, Chairman feces face Calais and turd master Ceo cook the book Fitzgerald, The only partnership for these individuals will be the federal state penn money laundering fraud where they will rot in hell getting there asses rapped by gorillas
👍️0
Atomic_Insider Atomic_Insider 3 días hace
Make it plain and simple for these money laundering fraud artists executives in management where is The patient that has remained on study the longest has, to date, received 7 doses each approximately 28 days apart over the approximately 7 months that this patient has been on study..where are those results before you decide to keep frauding investors …Conclusion…. Fraud since inception to funnel it all in their pockets
👍️0
Here Today Here Today 3 días hace
Pretty soon they will need to do a 400:1 reverse stock split!!!!
👍️0
MartinLutherKing MartinLutherKing 3 días hace
Where is big pharma partnership?Their fun and games with their peddlers investors ito fill up their personal ATM pocket financing has come to an end.. It’s do or die by the sword for management at this stage of their clinical trial hoax
👍️0
Atomic_Insider Atomic_Insider 5 días hace
RNAZ Founders and management’s money laundering cash cow scam machine so they can fill their pockets since it went public on 07/2021 They have made history in screwing investors on reversals on the guinness book of world records and is 1,056,000 shares to 1 since inception 3 years ago, a scam to screw all shareholders hard earned money since inception to funnel it all strait in founders pockets while they act like they are the victims of this crime
👍️0
Atomic_Insider Atomic_Insider 5 días hace
Let the dirty rat scavengers scam artist founders and management buyback their skin in the game shares instead of funneling the cash cow strait in their pockets while reversing the garbage truck to the dumpster
👍️0
Atomic_Insider Atomic_Insider 5 días hace
The world watches IHUB— Blame the criminals running this scam, in management Company history says it all.. Smells of shit since inception… Founders funneled over 100M in their pockets since inception and are pretending to be the victims of their own crimes…Bust their assholes in jail where the gorillas can tear apart their assholes
👍️0
tapioca tapioca 5 días hace
Then why is at .30 ? Pretty tough to be positive when they continue to decimate shareholders with non-stop reverse splits. So you’re blaming posters here for the current PPS? Smacks of desperation. Don’t worry no one reads this board.
👍️0
Atomic_Insider Atomic_Insider 5 días hace
That’s what happens with a cash cow funneling company, runned by camouflaged scam artists as highly skilled individuals… everyone involved in this company are scam artists specialists filling their pockets while they scam all of retail for the cause of curing cancer… Wow bust them all for fraud and make an example of them worldwide
👍️0
Atomic_Insider Atomic_Insider 5 días hace
These scavengers rat scam artists in management need to buy back shares from their own company if this technology truely is effective… the world knows the cash cow funneling criminals scam games to fill up their pockets while the pull the plug on all longs since inception period… Let them all rot in jail for fraud with all the rest of the micro Rna scientific community scam artists
👍️0
Atomic_Insider Atomic_Insider 5 días hace
Here are founding fathers of the funneling cash cow machine of the micro-Rna nobel prize clinical trial hoax designed since inception to fill up their pockets while they R/ S all their career achievements on all shareholders and act like they are the victims of this crime

Per the DEF14A, dated 4/11/
***As board members and managers, we are also shareholders and are fully aware of the pain such a decision causes."


Per the DEF14A, dated 4/11/2025:

• Thomas A. Fitzgerald owns 43 shares of Common Stock.

• Philippe Calais owns 5 shares of Common Stock.

• Erik Manting and Magda Marquet each own 0 shares of Common Stock.


Anna Moore: Co-Founder at Transcode Therapeutics
0 Shares

-Zdravka Medarova: Co-Founder at Transcode Therapeutics.
0 shares

-Michael Dudley: Co-Founder & CEO at Transcode Therapeutics.
0 shares

• Philippe Calais owns 5 shares of Common Stock.

• Erik Manting and Magda Marquet each own 0 shares of Common Stock.


Anna Moore: Co-Founder at Transcode Therapeutics
0 Shares

-Zdravka Medarova: Co-Founder at Transcode Therapeutics.
0 shares

-Michael Dudley: Co-Founder & CEO at Transcode Therapeutics.
0 shares
👍️0
Atomic_Insider Atomic_Insider 5 días hace
Nothing happened except they filled up their pockets with the cash cow money laundering machine, anything to screw shareholders to fill up their pockets while they make the public believe management has been been the victims of their own scam shit💩💩💩Jail is where they all deserve to be busting their asses wide open by a family of gorillas
👍️0
Atomic_Insider Atomic_Insider 5 días hace
No kidding after raising 20Million in the last weeks from the criminal funders, they funneled it strait in their personal pockets, they dried up the cash cow machine and these pharma junkies expect institutional support… Their scam shit has been identified as the MULN of the pharmaceuticals.. Slap management all in jail for fraud 💩💩💩💩💩
👍️0
Atomic_Insider Atomic_Insider 5 días hace
We supposed to be celebrating instead of eating craft dinner on the street with no underwears, Pit these criminals in jail for fraud
👍️0
Atomic_Insider Atomic_Insider 5 días hace
If this wasn’t a clinical trial scam brought to you by FDA And NIH and transcode money laundering therapeutics we would be in a different situation with big pharma buyout support
👍️0
Atomic_Insider Atomic_Insider 5 días hace
It’s all a lie for them to screw shareholders with the hope, these baboons in management are corporate criminals of the pharmaceutical nobel micro Rna prize scam of the century 💩
👍️0
Atomic_Insider Atomic_Insider 5 días hace
These criminal corporate junkies losers in management can’t do anything morality right for shareholders since inception, can’t you see what they have accomplished is a bankrupt piece of reversed shit 💩
👍️0
zeusgodmd zeusgodmd 5 días hace
You guys are way to negative for a med that has kept people alive for 7 months already with metastatic disease. I'm sure you're scaring people and buying up the shares.
👍️0
tapioca tapioca 5 días hace
Chances of this getting to a buck in the next 10 days are slim to none.
👍️0

Su Consulta Reciente

Delayed Upgrade Clock